CIDRAP newsletters options
The US Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) recently announced Nevada's first highly pathogenic avian flu outbreak in poultry, which struck a backyard flock in Carson City housing 40 birds.
Outbreaks involving the H5N1 strain have now been reported in 37 states and have led to the loss of more than 40 million birds.
Long-COVID patients in Israel who underwent hyperbaric oxygen therapy (HBOT) saw improvement in brain function and cognitive, psychiatric, and physical symptoms, according to a report published today in Scientific Reports.
Inhaled high-dose nitric oxide shortened time on supplemental oxygen and hospital stays.
Also, the CDC is partnering with Mayo Clinic to begin conducting tests for the virus.
The Biden administration announced this morning that it would buy 3.2 million doses of the Novavax COVID-19 vaccine, which is expected to soon receive authorization from the Food and Drug Administration, according to a Department of Health and Human Services (HHS) news release.
Parties, bath houses, saunas, and other mass-gathering sites have been implicated in transmission.
Phase 1 and 2 trials reveal inconclusive subjective results for the drug, which opens respiratory passages.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
The American Animal Hospital Association (AAHA) and the American Association of Feline Practitioners (AAFP) yesterday released new joint recommendations for judicious antibiotic use in cats and dogs.
Americans are not happy with the country's response to the COVID-19 pandemic, according to a new survey from Pew Research Center.
WHO data show that, among monkeypox patients with known HIV status, 41% are HIV-positive.
Researchers also estimate that vaccines averted 27 million infections and 1.6 million hospitalizations.
A study yesterday in The Lancet Infectious Diseases describes an ongoing outbreak of sexually transmitted, extensively drug-resistant (XDR) Shigella sonnei in the United Kingdom.
The experimental cancer drug sabizabulin slashed all-cause deaths by 55.2% over placebo in high-risk hospitalized COVID-19 patients by 60 days and was tied to fewer adverse events, according to interim results of a randomized, controlled phase 3 trial published yesterday in NEJM Evidence.
"Testing remains a challenge, and it's highly probable that there are a significant number of cases not being picked up."
BA.4 and BA.5—which now cause more than 70% of US cases—are 4 times more resistant to 3 vaccine doses than BA.2 is, and only 1 of 19 monoclonal antibodies tested showed efficacy against those subvariants.
In global developments, cases rose for the fourth straight week, led by the BA.4 and BA.5 Omicron subvariants.
Pre-Omicron, the leading causes of death were heart disease (20.1%), cancer (17.5%), and COVID-19 (12.2%).
The Global Plan to End TB 2023-2030 calls for a global investment of $250 billion.
A study in Ontario suggests that, compared with a third dose of mRNA COVID vaccine, a fourth dose improved protection against infection and severe outcomes among long-term care residents during the Omicron wave. The study was published today in The BMJ.
